About Us

Home >> News
News

Jan.16, 2020  Phagelux CEO Mark Engel interviewed at JP Morgan Conference. Phagelux looks to raise $20M USD plus, primarily to fund clinical trials. Phagelux clinical programs will uniquely address very large antibiotic resistant pathogen targets.



R&D Pipeline

Overall Pipeline Strategy: We are initially focused ion topical AMR infections since (a)  the size of the market is so large and (b) there are virtually no other affordable solutions, either on the market or under development, to treat or prevent such infections at a reasonable cost.  However, over time, in addition to our eczema and acne treatments, we will look to in-license later stage biological dermatological treatments for some underserved indications including for the following problems: additional AMR topical solutions, oncodermatology, actinic keratosis, and/or psoriasis. As we expand we will become one of the leading skin sciences companies in China.

Leveraging the Pipeline - Creating Revenue/Cash Flow from Out-licensing Platform Technologies: The Phagelux pipeline has considerable value, either for :

ROW – Skin Care Products:  All non-China rights will be open for out-licensing.  

Non-Core Best in Class Assets: All uses of lysin products for internal uses, whether in China or outside, will be available for out-license. Of particular value is Cly0, which is a Best-in-Class staph lysin. The second in class was out-licensed post-Phase I for $667M USD  (milestones plus low teens royalty). Sustained release for use on implants could also have significant value. 

Management Team

Mark Engel

CEO

Previously founded 4 successful life sciences companies

Dr. Nancy Tawil 

Chief Scientific Officer

Ph.D in Biomedical Engineering and Phage Expert



Dr. Assaf Raz

Lab Manager - Wuhan

Ph.D in Biology and Leading Global Lysin Expert



Sandy Li

Quality Manager

M.S. in Chemistry. Experienced in GMP

drug production



Dr. Iness Hammami

Vice-President, Research

Ph.D in Chemical Engineering.

10 years of experience in biopharmaceutical engineering



Key Advisors


Clinical Advisors:

Dr. Tan Linshi, Chairman, dMed (www.dmedglobal.com)

Dr. Chen Wei, Executive Director of Regulatory Affairs,  WuXi AppTec Regulatory Services (www.wuxiapptec.com)


Skin Care Commercial Advisors:

Robert Braithwaite, Founder and Chairman of Luqa Pharma


Banking Advisor - Global:

Dave Sebow, Head of Global Healthcare, Silicon Valley Bank


China Topical AMR Infections Advisors:

Dr. Zhu Tong Yu, President of Zhongshan Hospital 


China Burn Infection Advisor:

Dr. Huang Guangtao, expert on burns and phages (trained under Dr. Hu Fuquan at 3rd Military Medical University, the leading burn hospital in China)


IPO Advisors:

Michael Chui, Head of Healthcare Asia, Goldman Sachs

All existing major investors

Board Members

Edward Hu

CO-CEO of WuXi AppTec


Aaron Yu

Managing Director at

 Investment Department of Fosun Pharma


Mark Engel

CEO of Phagelux

Overview

Phagelux utilizes phages, lysins and other biologics and related delivery technologies to create novel antibacterial products and solutions. Phagelux particularly targets anti-microbial resistant pathogens. It has R&D centers in Montreal, Canada and Wuhan, China. The former is focused on bacteriophage products while the latter develops lysin products.


Phagelux has five products under various stages of development. The most advanced is our 14 phage cocktail to treat AMR infections in burn patients which is ready to start a phase one trial in Australia. This will be followed closely by our lead product which is a sustained release phage cocktail to prevent certain AMR infections associated with pressure ulcers. If clinical trials are successful for this indication, we plan to add labelling for the prevention of AMR infections in other indications.


Our lysin dedicated lab is working on several products that we believe will enter the clinic in 2021.


Technical Support: 赛泊斯 | Admin Login